Acutaas Chemicals Limited — PPTs, 02-05-2025: Investor Presentation

1. Financial Highlights:

Ami Organics Limited posted FY25 revenue of ₹1,006.9 Cr, up 40.3% YoY, crossing the ₹1,000 Cr milestone. EBITDA rose sharply by 80.6% YoY to ₹232.1 Cr, with margin expansion to 23.0%. PAT nearly doubled to ₹160.4 Cr (up 98.6% YoY), with PAT margin at 15.9%. Q4FY25 showed strong momentum: revenue increased 37.1% YoY to ₹308.5 Cr, EBITDA nearly doubled to ₹85 Cr (27.5% margin), and PAT grew 144.2% to ₹62.7 Cr. Gross margin improved to 47.3%. The balance sheet remains solid with equity at ₹1,320 Cr and low debt of ₹8.2 Cr, supporting growth with healthy capital structure and zero-liquid-discharge plants.

2. Strategic Initiatives & Growth Drivers:

Rebranding as Acutaas Chemicals Limited aligns with expansion into diversified specialty chemicals. FY26 guidance targets 25% growth driven by capacity ramp-up, utilization of new greenfield plants, and commercialization of advanced pharma intermediates plus specialty segments like semiconductor and battery chemicals. R&D spend sustained at 1.9% of revenue fuels innovation and cost leadership, supported by flow reactor technology reducing cycle times. The Ankleshwar plant commissioning and battery chemicals push are key growth engines.

3. Business Developments:

Acquisition of Baba Fine Chemicals advances entry into semiconductor chemicals. New manufacturing facility inaugurated in Ankleshwar expands capacity. The product portfolio now enjoys 15+ process patents in advanced pharma intermediates. Export sales contribution rose to 74%, supported by ~600 global customers across 55 countries. Battery chemical business accelerated via subsidiaries with approvals secured from six electrolyte additive customers.

4. Market Position & Competitive Advantage:

Ami Organics is a leader in advanced pharma intermediates, with 550+ specialized products focused on chronic therapies. It holds preferred supplier status with global innovators and generics. High entry barriers stem from complex chemical processes and niche regulatory compliance, safeguarding market position. Strong backward integration, innovation, and process expertise provide sustainable cost advantages and customer stickiness.

5. Investor Implications:

Robust financials, strategic capacity additions, and expanding specialty chemicals portfolio underpin positive growth potential. Strong export orientation and presence in semiconductor and battery segments add diversification and margin enhancement possibilities. Execution risks around ramping new capacities and product launches warrant monitoring, but a solid customer base and innovation pipeline support confidence in medium-term expansion and global market share gains.